IMPreT: In vitro Models for Precision Therapies

The KTH strategic research initiative IMPreT brings together world-leading expertise at KTH to develop advanced human in vitro models—such as organoids and organ-on-chip—for use in precision medicine and pharmaceutical research. Our vision is to become Sweden’s hub for developing and providing in vitro technologies that benefit both clinical practice and industry.

Sweden already has excellent Life Science infrastructure through SciLifeLab, strongly mediated by KTH, and programs like DDLS and WASP place us at the forefront of big data analysis. However, there is a lack of coordinated research into the foundational technologies for human-relevant in vitro models—critical tools for advancing biological insight and therapies beyond data generation.

KTH will lead efforts to address this gap by forming an excellence cluster focused on emerging technologies. IMPreT will drive technological innovation to:

Better mimic the cellular microenvironment,
Enable reproducible, spatially-resolved assays,
Apply AI and novel methods to interpret complex multicellular data.

By integrating multidisciplinary expertise and fostering academic, clinical, and industrial partnerships, both nationally and internationally, IMPreT will build holistic pipelines for model development, analysis, and data translation, ultimately establishing a national infrastructure for precision in vitro medicine.
IMPRET is interested in widening the network with academic, clinical and industrial collaborations.